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reduce mortality after injury. The TEG 5000 system is widely used for viscoelastic testing. However, the TEG 6s system incorpo-
rates newer technology, with encouraging results in cardiovascular interventions. The purpose of this study was to validate the TEG
6s system for use in trauma patients.METHODS: Multicenter noninvasive observational study for method comparison conducted at 12 US Levels I and II trauma centers. Agreement
between the TEG 6s and TEG 5000 systems was examined using citrated kaolin reaction time (CK.R), citrated functional fibrinogen
maximum amplitude (CFF.MA), citrated kaolin percent clot lysis at 30 minutes (CK.LY30), citrated RapidTEGmaximum amplitude
(CRT.MA), and citrated kaolinmaximum amplitude (CK.MA) parameters in adultsmeeting full or limited trauma team criteria. Blood
was drawn≤1 hour after admission. Assayswere repeated in duplicate. Reliability (TEG 5000 vs. TEG 6s analyzers) and repeatability
(interdevice comparison) was quantified. Linear regression was used to define the relationship between TEG 6s and TEG 5000 devices.RESULTS: A total of 475 patients were enrolled. The cohort was predominantly male (68.6%) with a median age of 49 years. Regression line
slope estimates (ß) and linear correlation estimates (p) were as follows: CK.R (ß = 1.05, ρ = 0.9), CFF.MA (ß = 0.99,ρ = 0.95), CK.
LY30 (ß = 1.01, ρ = 0.91), CRT.MA (TEG 6s) versus CK.MA (TEG 5000) (ß = 1.06, ρ = 0.86) as well as versus CRT.MA (TEG
5000) (ß = 0.93, ρ = 0.93), indicating strong reliability between the devices. Overall, within-device repeatability was better for
TEG 6s versus TEG 5000, particularly for CFF.MA and CK.LY30.CONCLUSION: The TEG 6s device appears to be highly reliable for use in trauma patients, with close correlation to the TEG 5000 device and
equivalent/improved within-device reliability. Given the potential advantages of using the TEG 6s device at the site of care, con-
firmation of agreement between the devices represents an important advance in diagnostic testing. (J Trauma Acute Care Surg.
2020;88: 279–285. Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Asso-
ciation for the Surgery of Trauma.)LEVEL OF EVIDENCE: Diagnostic test, level II.
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Volume 88, Number 2College of Surgeons Trauma Quality Improvement Program rec-
ommends the use of thromboelastography, if available, in its guide-
lines for patients at risk for massive transfusion following trauma.9
There are multiple platforms for viscoelastic testing, one
of which is the TEG 5000 Hemostasis Analyzer (Haemonetics
Corp., Braintree, MA). The TEG system is proven to be superior
to conventional coagulation testing in trauma patients10 as well as
in patients undergoing cardiac surgery11 and liver transplantation.12
Limitations of the TEG 5000 Hemostasis Analyzer include the
technical requirements of pipetting the blood sample, and vulnera-
bility tovibration. The TEG6sHemostasis Analyzer (Haemonetics
Corp.) was designed to eliminate these issues, to provide more
reliable measurements at the site of care. The TEG 6s Hemosta-
sis Analyzer uses resonance-frequency viscoelasticity measure-
ments and a disposable multichannel microfluidic cartridge that
eliminates pipetting and enhances portability, which potentially
decreases vulnerability to vibration and reduces user-error. It
also has the potential for assay-specific multichannel testing.
The TEG 6s system has been utilized to assess coagulation in
cardiovascular surgery and cardiovascular interventions11 and
has been shown to have a greater ease of use and precision when
compared with the TEG 5000 system in patients undergoing
coronary revascularization.13,14
Rapid and reliable assessment of coagulopathy is critical
to point-of-care resuscitation after injury. Although there are
substantial benefits to viscoelastic testing in trauma, and multi-
ple platforms exist for this testing, the adoption and integration
of this technology is still an ongoing process. The potential re-
duction in user-error and increased portability of the TEG 6s
system represent needed advances in point-of-care technology
available in the emergency department, operating room, and sur-
gical intensive care unit. Recent data suggest that use of the TEG
6s system during ground and air transport is feasible,15–17 provid-
ing the potential for viscoelastic testing in the prehospital setting
for the early identification of coagulopathy. However, to date, the
comparison of the TEG 6s Hemostasis Analyzer to the existing
TEG 5000 system technology for use in trauma has not been in-
vestigated. The purpose of the present study was to underscore
the utility and reliability of the TEG 6s system for use in trauma
patients via comparison to TEG 5000, as well as to assess the in-
ternal consistency of the TEG 6s device.
METHODS
Study Design
This trial was a multicenter, noninvasive, observational
study for method comparison purposes with minimal risk to the
patient. This method comparison was conducted according to
the Clinical and Laboratory Standards Institute Guideline
EP09-A2 Method Comparison and Bias Estimation Using Pa-
tient Samples18 to support the equivalence for assay measure-
ments of citrated kaolin reaction time (CK.R), citrated kaolin
percent clot lysis at 30 minutes (CK.LY30), citrated RapidTEG
maximum amplitude (CRT.MA), and citrated functional fibrin-
ogenmaximum amplitude (CFF.MA). These four measurements
were selected because they are included in major decisions re-
garding blood component administration and antifibrinolytics
in severely injured patients. The study was conducted at
12 American College of Surgeons verified or state designated280 © 2020 The Author(s). Published by Wolters Kluwer Health,Levels I and II Trauma Centers. Each center obtained institu-
tional review board (IRB) approval prior to initiation. The study
was performed under waiver of consent, and four of the IRBs re-
quested that study subjects (or legally authorized representa-
tives) be provided with a Study Information Sheet and be
provided the opportunity to withdraw from the study. The trial
data were used for a comparative analysis of the established
TEG 5000 system and the new TEG 6s Hemostasis Analyzer
in injured patients. The study examined the agreement between
TEG 5000 and TEG 6s systems coagulation analysis results.
Therewas no study intervention to the patient other than the col-
lection of blood sample(s) in three additional 4.5-mL, or five
2.7-mL vacutainers (3.2% sodium citrate, blue top). These sam-
ples were obtained, when feasible, with the standard of care
(SOC) blood draws. Blood samples from each subject were an-
alyzed in duplicate using the TEG 6s and TEG 5000 systems by
experienced research personnel. Investigators were blinded to
the TEG 6s analyzer results. No viscoelastic testing included
as part of this protocol was used to guide clinical care. Samples
were for research purposes only, and the decision to order visco-
elastic testing as part of clinical care was at the discretion of the
clinician and SOC for each institution. Samples were obtained
as soon as possible upon emergency department arrival but no
later than 1 hour after admission. Assessment of the agreement
between the TEG 6s and the TEG 5000 assay measurements
was performed by analyzing the relationship between the first
replicate of the TEG 6s analyzer and the mean of two replicates
of the TEG 5000 system.
Each assay and measurement is provided in an assay-
measurement format. So as an example, for CK.R, the assay is
CK and the measurement is R.
Study Oversight
Sites were required to complete instrument validation and
proficiency testing for all involved research personnel. Predefined
validation testing was completed for both of the TEG systems
prior to analysis of patient samples and data collection. Site profi-
ciencywas assessed using predefined proficiency assessments for
the correct use of the TEG 5000 and TEG 6s Hemostasis Ana-
lyzers. Central Statistical Risk Based Monitoring was conducted
on a periodic basis for all TEG device data for early detection
of data integrity and study center compliance issues, enrollment
monitoring, optimization of the site audit and retraining schedule,
and overall increase of the study final data quality.
Patient Population
Adult patients (males or females 18 years and older) who
met the full or limited trauma team criteria of the American Col-
lege of Surgeons or similar criteria established per institutional
guidelines were included. A small percentage of the study pop-
ulation was expected to have CK.LY30 values in the upper ana-
lytical measurement range (AMR) of the assay. If the number of
subjects with CK.LY30 levels in the upper and mid AMR was
below 10%, the inclusion criteria could be modified to enrich
for subjects with the desired CK.LY30 range. Enrichment
criteria included: systolic blood pressure < 90 mm Hg, base ex-
cess of <−6mEq/L,GlasgowComaScale (GCS) <6, or pH< 7.2
upon arrival to the trauma center. Adverse events related to veni-
puncture and medical device reports were recorded.Inc. on behalf of the American Association for the Surgery of Trauma.
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deemed unfit for participation in the study by the principal in-
vestigator, or if they were participating in another clinical trial
that would not be scientifically or medically compatiblewith this
study. Four of the IRBs requested that study subjects (or legally
authorized representatives) be provided with a Study Informa-
tion Sheet and be provided the opportunity to withdraw from
the study.
Testing and Data Processing
The citrated patient blood samples were tested concur-
rently in the TEG 6s system (using the Citrated Multichannel
Cartridge) and in the TEG 5000 system (using the following re-
agents: citrated RapidTEG, citrated kaolin, citrated kaolin in he-
parinase, and citrated functional fibrinogen).
Data for all thromboelastography measurements were re-
corded. Medications that could affect the coagulation status,
and any type of blood product and intravenous fluid adminis-
tered up to the point of blood draw for TEG testing were cap-
tured in the electronic case report form. Information collected
in the electronic case report form also included: demographic in-
formation, location/mechanism of injury, estimated time of injury,
hospital arrival time, TEG test blood sample collection time, patient
disposition at the TEG test blood draw, vital signs, conventional
coagulation tests including platelet count (if available), pro-
thrombin time/international normalized ratio (PT/INR), acti-
vated partial thromboplastin time (aPTT), and fibrinogen
levels, trauma assessments (Injury Severity Score [ISS], GCS),Figure 1. Comparison of TEG 6s vs. TEG 5000 Replicates for CK.R (pa
D). Axes numbers in bold indicate reference range; the overall range
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalfadmission status, all-cause mortality (through 24 hours), and if
available, the SOC hematocrit, SOC hemoglobin, and SOC
blood gas analysis results. Patients were not followed-up after
the blood sample for analysis had been obtained, except for as-
sessment of all-cause mortality at 24 hours, and number of units
of red blood cells administered in 24 hours, medical device
reporting events, and adverse events due to blood draws, if not
part of SOC.
Agreement Analysis
The analysis focuses on the agreement between the TEG
6s and TEG 5000 parameters, as well as on the internal replica-
bility of the two TEG 6s and two TEG 5000 measurements. The
primary analysis of the method comparison was based on agree-
ment between the first replicate of TEG 6s measurements and
the mean of the two TEG 5000 replicates. As the precision of
the TEG 5000 measurement depends on the operator, the mean
of two tests provides a more robust baseline for comparison,
while the TEG 6s is an automated, cartridge-based test and there-
fore the first samplewas prospectively determined to be used for
the comparison, as consistent with FDA standards for method-
comparison studies. The main criterion for assessment of the
agreement between the two devices was based on the assessment
of the predicted bias and its acceptability at the medical decision
points. The medical decision points were defined as the cutoff
points of the normal reference ranges. The predicted bias, de-
fined as the difference between the expectation of the test result
and the results of the reference test, was estimated using anel A), CFF.MA (panel B), CK.LY30 (panel C), and CRT.MA (panel
of graph is in line with the AMR.
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TABLE 1. Study Cohort Demographics
Variables Total Patients at All Centers (N = 475)
Female sex, n (%) 149 (31.4)
Age, median (IQR) 49 (18, 95)
Race, n (%)
Caucasian 345 (72.6%)
Black or African American 77 (16.2%)
Asian 11 (2.3%)
American Indian or Alaskan Native 3 (0.6%)





Not reported 9 (1.9%)





Alcohol use, n (%) 92 (19.4%)
GCS on admission, median (IQR) 15 (3, 15)
ISS, median (IQR) 10 (0, 75)
0, n (%) 8 (2.2%)
1–8, n (%) 133 (35.9%)
9–15, n (%) 90 (24.3%)
16–24, n (%) 66 (17.8%)
25–75, n (%) 74 (20.0%)
GCS, Glasgow Coma Scale; IQR, interquartile range; ISS, injury severity score.
Neal et al.
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tween the TEG 6s and TEG 5000 measurements. Deming regres-
sion was the default method and Passing-Bablock regression was
used in the event of nonnormality of bias distribution.
The secondary assessment of the agreement between the
devices included bias estimation at the AMR, estimates of the
coefficients defining the linear relationship between the devices,
Pearson correlation coefficient estimates, visual assessment of
the agreement suggested by agreement plots (Fig. 1), and error
analysis including Bland-Altman Plots (Supplemental Digital
Content 1, Fig. 1, http://links.lww.com/TA/B499).
Analysis of within device agreement (or replicability)
using the two replicates of the same measurement included cor-
relation analysis, agreement of the replicates assessed by means
linear regression, visual analysis of the replicates and regression
line estimates, predicted bias analysis (second replicate vs. first
replicate taken as a reference measurement) at medical decision
points and AMRs, and error analysis with Bland-Altman plots
(Supplemental Digital Content 2, Figs. 2 and 3, http://links.
lww.com/TA/B500).
The target enrollment sample size was approximately 500
subjects allowing up to a 20% drop out rate. The sample sizewas
estimated using historic variability of the TEG parameters under
consideration. In areas where there were insufficient clinical
samples, data from donor samples that were modified in vitro
were used to supplement patient samples, in accordance with
the protocol and within the prespecified limits. This supplemen-
tation was limited to an addition of up to 10% of the samples, in
line with generally accepted best practice.
RESULTS
Patient Cohort
A total of 475 patients were enrolled across all centers.
Demographics for the study population are presented in
Table 1. The cohort was predominantly male (68.6%) with a me-
dian (interquartile range) age of 49 years (18–95 years). Most in-
juries were due to a blunt mechanism (78.1%) and the overall
mortality at 24 hours was 3.4%. A total of 43.3% of patients re-
quired ICU admission. The mean (standard deviation [SD]) GCS
score was 12 (4) and the mean (SD) ISS was 14 (13) with 20.0%
of patients having an ISS greater than 25. There was one study-
related adverse event in this study. A subject was reported to have
a ruptured vein and severity was assessed as mild. There were no
medical device and incident reports recorded in the study.
TEG 5000 versus TEG 6s Device Comparison
Linear regression analysis demonstrated strong reliability
between the first replicate of the TEG 6s system and the mean of
two replicates of the TEG 5000 system with regression line
slope estimates (ß) and linear correlation estimates (ρ) as fol-
lows: CK.R (ß = 1.05, ρ = 0.9), CFF.MA (ß = 0.99,
ρ = 0.95), CK.LY30 (ß = 1.01, ρ = 0.91), CRT.MA (TEG 6s)
versus CK.MA (TEG 5000) (ß = 1.06, ρ = 0.86) as well as ver-
sus CRT.MA (TEG® 5000) (ß =0.93 and ρ = 0.93) (Fig. 1 and
Supplemental Digital Content 3, Figure 4, http://links.lww.com/
TA/B501). The quantitative analysis presented for CK.LY30
represents 86 total samples where the LY30 was greater than
1.25%. Measurements below 1.25% are classified as “low CK.282 © 2020 The Author(s). Published by Wolters Kluwer Health,LY30 values” for the purpose of this method comparison
study and are treated in the framework of a qualitative
agreement analysis due to increased variability below this
measurement. Measurements above 1.25% are treated in the
same framework as the other parameters' analyses. There
were 301 samples with TEG 6s CK.LY30 values below the
1.25% cutoff point. Of these 301 samples, 255 (85%) had TEG
5000 CK.LY30 values (in replicate 1) that were also below
1.25%. Therefore, there was agreement in 85% of the samples in
the qualitative analysis. Among the remaining 46 samples (15%
of 301) that were below 1.25%, 34 were within the normal
reference range (0–2.6) and only 12 (4%) of the samples were
above the 2.6% cutoff point value for normal reference range.
Therefore, in 96% of samples, the TEG 6s as well as the TEG
5000 CK.LY30 values were in agreement with each other with
respect to falling within the normal reference range. The predicted
bias at the medical decision points for all the parameters met the
predefined bias acceptance criteria. The summary of method
comparison analysis, analysis of within device variability, and
bias estimates are shown in Supplemental Digital Content 4,
Tables 1–3, http://links.lww.com/TA/B502.
Overall within-device repeatability (as judged by regres-
sion line slope estimate, Pearson correlation analysis, and pre-
dictive bias at the medical decision limits) was excellent for all
measurements (Table 2). However, the analysis of the within de-
vice agreement (or replicability), based on the agreement of the
two replicates of the same device, suggests that the TEG 6sInc. on behalf of the American Association for the Surgery of Trauma.
TABLE 2. Analysis of Within Device Variability for the TEG 6s and TEG 5000 Hemostasis Analyzers
TEG 6s TEG 5000
Measurements Correlation, p (95% CI) Slope, ß (95% CI) Correlation, p (95% CI) Slope, ß (95% CI)
CK.R (n = 425) 0.9 (0.87–0.91) 0.96 (0.92–1.01) 0.99 (0.98–0.99) 0.99 (0.97–1.01)
CFF.MA (n = 424) 0.99 (0.99–0.99) 1.0 (0.98–1.01) 0.97 (0.96–0.97) 0.99 (0.96–1.01)
CRT.MAvs. CK.MA (n = 406) 0.95 (0.94–0.96] 1.12 (1.09–1.16) 0.78 (0.74–0.81) 1.12 (1.03–1.2)
CRT.MA (n = 413) 0.99 (0.98–0.99) 1.0 (0.98–1.02) 0.9 (0.88–0.92) 0.95 (0.91–1)
CK.LY30 (n = 81) 0.88 (0.82–0.92) 1.04 (0.92–1.17) 0.71 (0.59–0.81) 1.32 (1.03–1.6)
CI, confidence interval.
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analyzer. The visual analysis of the two device replicates, pre-
sented in Supplemental Digital Content 5, Figures 5 and 6,
(http://links.lww.com/TA/B503) shows that replicates of all
TEG 5000 parameters, except CK.R, apparently have a higher
variability (or spread) compared with TEG 6s parameters. The
higher consistency of the TEG 6s can also be supported by the
correlation analysis presented in Table 2. This analysis shows
that the two replicates of TEG 6s parameters (except CK.R)
not only have better estimates of the Pearson correlation coeffi-
cient but also the variance of the estimates is much smaller as
implied by the length of the confidence intervals associated with
the correlation coefficients. The analysis of the tracings (data
not shown) of the TEG 5000 and TEG 6s replicates revealed that
device- or operator-related tracing abnormalities are much more
frequent in the TEG 5000 system compared with the TEG 6s
system, with the latter having only a few failures.
DISCUSSION
In this method comparison study, the TEG 6s device was
found to have excellent reliability when compared to the TEG
5000 device in a representative cohort of injured patients. Within
device repeatability for CFF.MA and CK.LY30 appeared to be bet-
ter (as judged by the regression line slope estimate and the predic-
tive bias at the medical decision limits) for the TEG 6s device
versus the TEG 5000 device, while the CK.R repeatability was
slightly better for the TEG 5000 device versus TEG 6s device.
Within device repeatability, comparing CRT.MA versus CK.MA
was very similar for both devices. Pearson linear correlation coeffi-
cient estimateswere above 0.9 for all measurements comparedwith
their counterparts of the same assays (CK.LY30 vs. CK.LY30, CK.
R vs. CK.R, CFF.MAvs. CFF.MA, and CRT.MAvs. CRT.MA).
In this study, subjects were chosenwhomet the full or lim-
ited trauma team activation criteria and were treated in Level I or
II Trauma Centers. These eligibility criteria were intended to re-
sult in a quantitatively adequate representation of the general
trauma patient population, including more severely injured pa-
tients who would potentially benefit from coagulation analysis
with the TEG system. The trauma study population for this
study provided adequate representation of the target ISS distri-
bution. In general, the patient population with reported ISSs in
this study showed a slightly more even distribution among the
different severity categories than the distribution reported in
the National Trauma Database 2016 report.19 Severely and very
severely injured cohorts were well represented with observed© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalfpercentages higher than in the historic trauma database19 as
would be expected based on our eligibility criteria of full or lim-
ited trauma team activation.
Validation of the TEG 6s device for use in trauma repre-
sents an important advance in viscoelastic testing and trauma
care. Although the TEG 6s and TEG 5000 devices have recently
been shown to have strong correlation in a small ICU cohort
study,20 this study represents the first analysis of its kind specif-
ically focusing on trauma. A major potential advance for the
TEG 6s device in trauma is a move toward more coagulation as-
sessment at the site of care, as has been shown to be feasible in a
small cohort study of trauma activations.21 The better perfor-
mance profile of the TEG 6s device for most measures com-
pared with the TEG 5000 system may be due to the design
features which avoid dependence on technical skills in pipet-
ting and susceptibility to vibration. These are particularly impor-
tant advances toward the use of viscoelastic testing in prehospital
care, and the TEG 6s device has recently been tested in simulated
environments of aeromedical evacuation,16,17,22 and in preclinical
models of ground and air medical transport.15 Taken together
with the results of the present analysis, the TEG 6s device may
be considered a reliable viscoelastic platform and diagnostic for
trauma patients with potential for use at the site of care. The im-
proved platform may allow for broad utilization of the device by
health care professionals beyond laboratory technicians.
A recent study of a smaller sample size (n = 67 patients)
by authors with clinical experience with both TEG and ROTEM
devices compared the TEG 6s and the ROTEM Sigma devices
in trauma.23 Strong correlations were observed between the
measured parameters of the two devices, except in the case of
EXTEM versus the rapid TEG which are different methodolo-
gies that do not align as well. Correlation of less strength was
also found for angle, a parameter that was not part of this study.
Comparison studies have also been carried out between the
ROTEM Sigma and its predecessor, the ROTEM delta, which
showed good correlation between the two platforms.24 However,
this single-center trial did not contain enough patients (n = 30) to
validate the reference ranges,25 method comparison for parame-
ters was performed as a bundle across different assays, and crit-
ical clinical decision points differed between the two devices.
For the present multicenter study at 12 clinical sites, we enrolled
475 patients to ensure the comparison was sufficiently powered,
and adhered to the FDA guidance for method comparison stud-
ies for diagnostic devices.
This study has important limitations. The correlations be-
tween the TEG 6s and TEG 5000 systems were lowest for CK.of the American Association for the Surgery of Trauma. 283
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and between device comparisons. The low number of patients
with hyperfibrinolysis (CK.LY30 > 2.6%) limits the assessment
of the TEG 6s systems reliability in this cohort. Although the
TEG 5000 device has previously been compared with conven-
tional coagulation testing and found to be clinically superior for
use in trauma,10 these comparisons remain untested for the TEG
6s device, although the strong correlation between the TEG 6s
and TEG 5000 devices suggests that similar results may be ex-
pected. Although the study was conducted in multiple centers
with a heterogeneous population of trauma patients, each of the
centers has experience with the clinical use of TEG 5000 device
for trauma, so the applicability of the results to centers with less
experience with viscoelastic testing remains untested. Certain pa-
rameters that are available on the TEG 5000 analyzer (such as an-
gle, K-time, ACT) were not studied and have not been included in
the regulatory filing for clearance in a trauma setting.26
In conclusion, the TEG 6sHemostasis Analyzer appears to
be highly reliable for use in trauma patients, with close correlation to
the TEG 5000 device as well as equivalent, if not improved, within-
device reliability. Given the potential advantages of the TEG 6s
device for use at the site of care, the confirmation of agreement
between the TEG 6s and TEG 5000 systems in trauma represents
an important advance in diagnostic testing for injured patients.
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